Global Prostate Cancer PARP Inhibitor Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Prostate Cancer PARP Inhibitor Drugs Market Research Report 2024
Poly ADP-ribose polymerase (PARP) is a DNA repair enzyme involved in the single-strand repair process of DNA. PARP inhibitors (PARPi) inhibit PARP activity through two mechanismsdirect inhibition of PARP function and PARP trapping, resulting in the stalling and collapse of replication forks, resulting in fatal double-strand breaks. Normal cells can repair double-strand breaks in time and correctly through homologous recombination repair (HRR); however, in tumor cells carrying HRR gene mutations, due to the impairment or loss of HRR function, the accumulated double-strand breaks will not be repaired in time and correctly, resulting in The tumor cell genome is unstable and eventually induces tumor cell death.
According to Mr Accuracy reports’s new survey, global Prostate Cancer PARP Inhibitor Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prostate Cancer PARP Inhibitor Drugs market research.
Key manufacturers engaged in the Prostate Cancer PARP Inhibitor Drugs industry include AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc and Jiangsu Hengrui Pharmaceuticals Co., Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Prostate Cancer PARP Inhibitor Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Prostate Cancer PARP Inhibitor Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostate Cancer PARP Inhibitor Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Merck & Co., Inc
GSK
Pfizer
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene, Inc
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Segment by Type
Lynparza
Zejula
Talzenna
Fluzoparib
PamiPali
Other
Hospital
Specialty Clinic
other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prostate Cancer PARP Inhibitor Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Prostate Cancer PARP Inhibitor Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prostate Cancer PARP Inhibitor Drugs market research.
Key manufacturers engaged in the Prostate Cancer PARP Inhibitor Drugs industry include AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc and Jiangsu Hengrui Pharmaceuticals Co., Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Prostate Cancer PARP Inhibitor Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Prostate Cancer PARP Inhibitor Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Prostate Cancer PARP Inhibitor Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Merck & Co., Inc
GSK
Pfizer
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene, Inc
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Segment by Type
Lynparza
Zejula
Talzenna
Fluzoparib
PamiPali
Other
Segment by Application
Hospital
Specialty Clinic
other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prostate Cancer PARP Inhibitor Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices